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Catheter-associated urinary tract infections (CAUTIs) are one of the most common
healthcare-associated infections in the US, accounting for over 1 million cases annually
and totaling 450 million USD. CAUTIs have high morbidity and mortality rates and can be
caused by a wide range of pathogens, making empiric treatment difﬁcult. Furthermore,
when urease-producing uropathogens cause symptomatic CAUTI or asymptomatic
catheter colonization, the risk of catheter failure due to blockage increases. The
enzyme urease promotes catheter blockage by hydrolyzing urea in urine into ammonia
and carbon dioxide, which results in the formation of crystals that coat the catheter
surface. If CAUTI is left untreated, the crystals can grow until they block the urinary
catheter. Catheter blockage and subsequent failure reduces the quality of life for the
chronically catheterized, as it requires frequent catheter exchanges and can promote
more severe disease, including dissemination of the infection to the kidneys or
bloodstream. Thus, understanding how urease contributes to catheter blockages and/
or more severe disease among the broad range of urease-producing microbes may
provide insights into better prevention or treatment strategies. However, clinical assays
that detect urease production among clinical isolates are qualitative and prioritize the
detection of urease from Proteus mirabilis, the most well-studied uropathogenic urease
producer. While urease from other known urease producers, such as Morganella
morganii, can also be detected with these methods, other uropathogens, including
Staphylococcus aureus and Klebsiella pneumonia, are harder to detect. In this study,
we developed a high throughput, semiquantitative assay capable of testing multiple
uropathogens in a rapid and efﬁcient way. We validated the assay using Jack Bean
urease, the urease producing species: Proteus spp., M. morganii, K. pneumonia, and S.
aureus strains, and the non-urease producer: Escherichia coli. This modiﬁed assay more
rapidly detected urease-producing strains compared to the current clinical test,
Christensen Urea Agar, and provided semiquantitative values that may be used to
further investigate different aspects of urease regulation, production, or activity in these
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diverse species. Furthermore, this assay can be easily adapted to account for different
environmental stimuli affecting urease production, including bacterial concentration,
aeration, or addition of anti-urease compounds.
Keywords: urease, urease detection assay, urease-producing uropathogens, CAUTI, Staphylococcus aureus,
Proteus spp., Klebsiella spp., Morganella spp.

Morganella morganii, and Staphylococcus aureus (Hedelin, 2002;
Broomﬁeld et al., 2009). Speciﬁcally, urease hydrolyzes urea,
present in urine, into ammonium and carbon dioxide, which in
turn, drastically increases the pH of urine and results in crystalline
precipitate formation. Accumulation of crystalline precipitates on
the catheter surface leads to urinary catheter encrustations
(Figure 1) and, if the infection is left untreated, can result in
catheter blockages and failure of the device (Gatermann et al.,
1989; Gatermann and Marre, 1989; Stickler and Feneley, 2010;
Konieczna et al., 2012; Armbruster et al., 2014; Armbruster et al.,
2017). With urinary catheter use expected to increase as the
population ages, CAUTI, and therefore catheter blockages, are
likely to become more common (Trautner, 2010). Thus, greater
insights into the mechanisms that promote CAUTI with urease
producing pathogens are urgently needed.
Urease is a highly conserved, nickel-containing enzyme that is
composed of three subunits, subunit a, subunit b, and subunit g,
and multiple accessory proteins. The gene ureC encodes the active
site (subunit a), which hydrolyzes urea. Together with the genes
encoding ureA (subunit g) and ureB (subunit b), the a, b and g
subunits form the apoenzyme, which is inactive. The additional
accessory genes, ureD, ureE, ureF, ureG, and ureH, which encode
additional metal coordination sites, are needed to form the fullyfunctioning holoenzyme and enable urease activity (Konieczna
et al., 2012). Despite being highly conserved across many CAUTI
pathogens, only the urease encoded by Proteus mirabilis is well
characterized among urease-producing uropathogens (Broomﬁeld
et al., 2009; Kosikowska and Berlicki, 2011; Konieczna et al., 2012;
Armbruster et al., 2014). Studies investigating the P. mirabilis
enzyme have shed light on how urease not only contributes to
catheter encrustations, but also irritates the mucosal epithelium,
exacerbates inﬂammation, and provides additional surfaces for
bioﬁlm formation (Gatermann et al., 1989; Gatermann and
Marre, 1989; Stickler and Feneley, 2010; Konieczna et al., 2012;
Armbruster et al., 2014; Armbruster et al., 2017). Additional studies
dissecting the regulation of P. mirabilis urease indicate that the
transcriptional activator UreR, which is encoded directly upstream
of the operon, is induced by the presence of urea (Nicholson et al.,
1993; Dattelbaum et al., 2003; Konieczna et al., 2012). Thus, when P.
mirabilis is grown in the presence of urea, urease is expressed.
Notably, while probe-based DNA-hybridization assays and
bioinformatics analyses indicate that other Proteus spp, including
P. vulgaris and P. rettgeri, and Providencia spp., such as P. stuartii,
also encode ureR homologues, other urease-producing CAUTI
pathogens, like M. morganii, S. aureus, and K. pneumoniae, do
not (Dattelbaum et al., 2003; Konieczna et al., 2012). Recent work
suggests M. morganii urease expression is constitutive, while K.
pneumoniae urease may be controlled through the nitrogen

INTRODUCTION
More than 30 million urinary catheters are placed annually in the
US, and of these, 10-30% become infected (Darouiche, 2001;
Trautner and Darouiche, 2004; Nicolle, 2012; Flores-Mireles
et al., 2015; Klein and Hultgren, 2020). These high infection
rates result in more than 1 million cases annually, making
catheter-associated urinary tract infection (CAUTI) the most
common hospital-associated infection in the US (Ronald, 2003;
Trautner and Darouiche, 2004; Cope et al., 2009; Trautner, 2010;
Nicolle, 2012; Flores-Mireles et al., 2015; Chenoweth and Saint,
2016). With an annual cost of 450 million USD, which as of 2008
is no longer reimbursable under the Center for Medicare and
Medicaid Services, CAUTI prevention has become a priority
(Peasah et al., 2013; Meddings et al., 2014). However, prevention
and treatment of CAUTI remains challenging for several reasons.
First, urinary catheters increase the range of pathogens capable of
causing urinary tract infections (UTIs), which makes empiric
treatment difﬁcult (Ronald, 2003; Trautner and Darouiche, 2004;
Nicolle, 2012; Flores-Mireles et al., 2015; Pelling et al., 2019).
Speciﬁcally, while UTIs in normal healthy individuals are
primarily caused by Escherichia coli (>80%), no single
pathogen accounts for >25% of all CAUTIs (Wagenlehner
et al., 2012; Weiner et al., 2016). Furthermore, while the
majority of pathogens causing CAUTI only account for 2-10%
of infections each, that translates to thousands of cases caused by
each species annually. Second, CAUTI pathogens form
recalcitrant bioﬁlms on the catheter surface that impair
antibiotic activity (Trautner and Darouiche, 2004; Nicolle,
2012; Flores-Mireles et al., 2015). Additionally, increasing
antibiotic resistance among uropathogens further complicates
treatment options. Recent work shows that empiric antibiotic
treatment of CAUTI fails to improve patient outcomes and may
result in additional complications, such as the development of
Clostridium difﬁcile diarrhea and/or antibiotic resistance (Babich
et al., 2017). Lastly, urinary catheters increase the rate of
symptomatic UTI and asymptomatic bacteriuria (ASB), with
chronically catheterized individuals at highest risk (FloresMireles et al., 2015; Nicolle, 2019).
For individuals with chronic indwelling urinary catheters, ASB
can also lead to catheter blockages, which decreases the quality of
life for these individuals as it results in frequent device failure and
increases the risk of additional complications, such as the
development of pyelonephritis and bacteremia (Warren et al.,
1994; Broomﬁeld et al., 2009; Stickler and Feneley, 2010). Catheter
blockages are typically caused by encrustations that form following
infection with CAUTI pathogens that encode the enzyme urease,
including Proteus spp., Providencia spp., Klebsiella pneumoniae,

Frontiers in Cellular and Infection Microbiology | www.frontiersin.org

2

March 2022 | Volume 12 | Article 859093

Duran Ramirez et al.

Semi-Quantitative Urease Detection Assay

FIGURE 1 | Catheter Encrustation. Scanning electron microscope (SEM) image of crystalline precipitates forming a catheter encrustation (green) resulting
from asymptomatic catheter-associated bacteriuria caused by Staphylococcus aureus (pink). The encrustation and bacteria are surrounded by host immune
cells (gray).

by placing the bacteria in RUT media, which contains an
antibacterial agent, urea, and a pH indicator. The sample is
then incubated at 38°C for no more than 24 hours (Uotani and
Graham, 2015). Here again, if a urease producer is present, urea
hydrolysis results in a color change of the media due to the pH
indicator. The RUT urease test is dependent on the initial
concentration of the bacteria used, and similarly to the
Christensen Urea Agar method, can also be affected by other
bacterial byproducts that change the pH of the media.
Speciﬁcally for the RUT media, any color change after the 24
hour time limit is considered a false positive (Uotani and
Graham, 2015). Thus, these assays are adept at identifying high
urease producers, generally with constitutive or urea inducible
expression, like Proteus spp., M. morganii, or H. pylori, and
provide qualitative results. However, for other urease-producing
uropathogens that do not encode the ureR gene, which
upregulates urease production in the presence of urea, such as
S. aureus and K. pneumonia, these assays are not as accurate at
detecting urease. Speciﬁcally for S. aureus, the Christensen Urea
Agar method only detects urease production in 25-50% of
clinical isolates, yet bioinformatics analyses suggest the operon
is present in >90% of all S. aureus strains sequenced and
annotated in NCBI as of 2012 (Bichler et al., 2002; Gad et al.,
2009; Konieczna et al., 2012; Flannigan et al., 2014).
Furthermore, in addition to these clinical assays, phenol redbased broth assays have also recently been developed to provide
semi-quantitative methods that allow researchers to further
dissect urease regulation, expression, and activity (Richmond
and Yep, 2019; Brauer et al., 2020; Sigurdarson et al., 2020).
These broth-based assays rely on detecting the optical density
(OD) at a single wavelength (between OD550 and OD570) to

regulatory system (Hu et al., 1990; Collins et al., 1993; Nicholson
et al., 1993; Dattelbaum et al., 2003). Additionally, previous studies
suggest several regulators may control S. aureus urease expression,
including the global regulators CodY and CcpA, as well as the Agr
quorum sensing system (Seidl et al., 2009; Zhou et al., 2019). Thus,
these studies not only indicate that urease is regulated differently
within these uropathogens, but they also suggest that the current
activity assays used to detect urease may fail to account for the
different signals needed to activate the expression, production, or
activity of urease within these diverse species.
Current clinical urease assays are qualitative and include the
Christensen Urea Agar method, primarily used for detection
among uropathogens, as well as the rapid urease test (RUT),
which is typically used for Helicobacter pylori, a bacterium that
infects the stomach (Christensen, 1946; Brink, 2013; Uotani and
Graham, 2015). Brieﬂy, the Christensen Urea Agar method is
performed by streaking a single bacterial colony onto an agar
slant or plate that contains urea, glucose, peptone, salts, and a pH
indicator (phenol red) (Christensen, 1946). The slant is then
incubated at 37°C and observed for up to 6 days. For urease
producing bacteria, the hydrolysis of urea within the agar by the
enzyme causes an increase in pH, which results in a color change
due to the presence of the pH indicator in the media. Thus, this
assay identiﬁes inducible or constitutive urease producers, like
Proteus spp. and M. morganii, within a few hours of incubation.
However, false positives can result after long incubation periods
due to the production of growth byproducts that also change the
pH of the media, thus a non-inoculated or a known non-urease
producer control slant is required to account for any non-urease
speciﬁc color change of the media. Similarly, the RUT assay,
which is primarily used to detect H. pylori urease, is performed
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the assay correlated with quicker detection of urease activity
among all strains tested, except for the non-urease producer,
E. coli, which remained negative for urease. Furthermore, urease
activity among all strains and species tested was detected more
quickly in the adapted assay compared to the Christensen Urea
Agar method. Notably, we found that urease could be detected
among all of the S. aureus urinary catheter-associated isolates
(7/7), regardless of the assay used. However, urease activity was
again detected more quickly with our adapted assay (5-10 hours on
average) compared to the Christensen Urea Agar assay (>24 hours).
Together, this data suggests urease production and activity among S.
aureus urinary catheter-associated isolates may differ from other
non-UTI related S. aureus strains. Thus, this work demonstrates
that the modiﬁed urease detection assay is an adaptable, high
throughput method that can rapidly detect urease activity among
a diverse array of urease-producing CAUTI pathogens, which can
be used in future studies to investigate urease expression,
production, and activity, and may even be adapted to explore
therapeutics with inhibitory capabilities.

determine the color change of the media, which provides semiquantitative values for urease activity. However, these methods
were primarily developed to assess urease activity among
individual pathogens that are generally considered high urease
producers, like P. mirabilis. Notably, bacterial species without
urea inducible or constitutively active urease enzymes, such as S.
aureus, remain untested in these assays (Richmond and Yep,
2019; Brauer et al., 2020; Sigurdarson et al., 2020). It, therefore,
remains unclear if these newly developed assays can be used to
semi-quantitatively detect urease among all pathogens that
produce the enzyme, especially considering these methods use
a single OD wavelength, which may also be affected by bacterial
growth or the production of growth byproducts that alters the
color change of the media, similarly to the Christensen Urea
Agar Assay.
Here, we set out to develop a high throughput, adaptable assay
to more rapidly detect and quantify urease produced by diverse
species, as well as to account for a wider range of culture
conditions than the previously developed tests. Speciﬁcally, we
adapted the Christensen Urea Agar assay to a 96 well plate broth
assay, with the color change detected by a microtiter plate reader.
The microtiter plate allows for the collection of semiquantitative
values that are associated with urease speciﬁc color change caused
by the increase in pH of the media. This adapted assay allowed for
the easy manipulation of culture conditions, such as varied
bacterial concentration and aeration, as well as the use of
additional controls, including the use of media with and without
urea, for more accurate detection of urease production in a
broader range of uropathogens. Using this assay, we assessed a
diverse set of CAUTI pathogens for urease production, including
Proteus spp., M. morganii, S. aureus, K. pneumoniae, and E. coli.
We found that increasing concentrations of bacteria at the start of

MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
All strains used in this study are listed in Table 1. All human
urinary catheter (HUC) clinical isolates, including strains of S.
aureus and M. morganii, were isolated from individuals with
chronic indwelling urinary catheters as previously described
(Walker et al., 2017; Walker et al., 2020). The Escherichia coli
strain was isolated from a woman who experienced a UTI (Chen
et al., 2009). The K. pneumonia strain was isolated from the
respiratory tract of an asymptomatic individual and provided by

TABLE 1 | Strain list.
Strain Name

Isolation site

Genus

Species

Staphylococcus
Staphylococcus
Staphylococcus
Staphylococcus
Staphylococcus
Staphylococcus
Staphylococcus
Staphylococcus
Staphylococcus
Staphylococcus
Staphylococcus
Staphylococcus
Klebsiella
Morganella
Proteus spp

aureus
aureus
aureus
aureus
aureus
aureus
aureus
aureus
aureus
aureus
aureus
aureus
pneumonia
morganii

Bae et al., 2008
This Study
Walker et al., 2017
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
Shropshire et al., 2021
This Study
This Study

DH5a

skin infection
skin infection
Urine
Urine
Urine
Urinary Catheter
Urinary Catheter
Urinary Catheter
Urinary Catheter
Urinary Catheter
Urinary Catheter
Urinary Catheter
Respiratory tract
Urinary Catheter
Urinary
Catheter*
Cloning strain

Escherichia

coli

RN4420
UTI89

Cloning strain
UTI

Staphylococcus
Escherichia

aureus
coli

Invitrogen cat #
LS18265017
Walker et al., 2013
Chen et al., 2009

JE2
JE2 ureC::tn
UTI MRSA
UTI MRSA ureC::tn
UTI MRSA DureC
HUC 86
HUC 86-02
HUC 95
HUC 97-02
HUC 100
HUC 100-01
HUC 111-01C
C699
HUC 87
JNW153

Citations

A total of 15 strains representing four species were tested to validate the adapted urease activity assay.
*mouse catheter.
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Drs. Cesar Arias and Blake Hanson (Shropshire et al., 2021). The
Proteus spp. strain was isolated from a mouse urinary catheter
during experimental urinary catheterization. Brain heart
infusion (BHI) broth (BD, cat # 237200) and BHI agar were
used to maintain all cultures and prepare overnight cultures for
experiments. All transposon mutants were generated using
tryptic soy broth (Sigma; cat # C1016-500G) and maintained
in BHI supplemented with 10 ug/mL erythromycin (Fisher; cat #
AC227330050). The ureC clean deletion was generated in
Escherichia coli under selection with 100 ug/ml ampicillin
(Sigma, cat #BP1760-25G) in LB (Sigma; cat #BP1426-500)
and then maintained in S. aureus under selection with 20 ug/
ml chloramphenicol (Sigma; cat # CO37825G) in BHI. Once
generated in the UTI MRSA background, the ureC clean deletion
was maintained in BHI without antibiotic selection. Christensen
Urea Agar (Sigma, cat # 27048-500G-F) plates and slants
supplemented with ﬁlter sterilized 40% urea solution were used
according to the manufactures protocol to determine urease
activity. Brieﬂy, slants and plates were inoculated with a single
colony from a BHI agar plate and incubated at 37°C for 50 hours.
For adapted urease activity broth assays, BHI broth was
inoculated with a single colony from a BHI agar plate and
grown, shaking at 175 rpm for at least 18 hours at 37°C.
Bacterial strains were then either i) spun down at 10,000 g and
resuspended or ii) diluted to various concentrations in urease
broth. Urease broth consisted of 1 g peptone (BD; cat # 211921),
1 g D(+)-glucose (Sigma; cat #G8270-1KG), 2 g potassium
phosphate monobasic (Sigma; cat # P9791-100G), 5 g sodium
chloride (Fisher; cat # S671-500), 0.012 g Phenol red (Sigma; cat
# 114529-5G), in 1 L of MilliQ water, pH 6.8. Following
sterilization via autoclaving, urease broth was either
supplemented with ﬁlter sterilized 40% urea solution (Fisher;
cat # BP169-500) or with an equivalent amount of sterile water
(the solution urea was dissolved in). Urease broth with and
without urea allowed the determination of urease-speciﬁc
activity across diverse bacterial species. Potassium phosphate
monobasic was a key component in the broth. When lower grade
or a different type of phosphate was used, the timing and/or the
intensity of the color change of the media was altered. Since this
assay relies on a pH change in the media following urea
hydrolysis by urease, the buffering capacity of each phosphate
may contribute to any difference observed.

Scanning Electron Microscopy Image of
Catheter Encrustation
The human urinary catheter was previously collected and clinical
characteristics were published (catheter #7) (Walker et al., 2020).
Scanning electron microscopy (SEM) was performed as
previously described (Walker et al., 2017; Walker et al., 2020).
Brieﬂy, a 3 cm long piece of the tip of the urinary catheter was
ﬁxed in 10% neutral buffered formalin, washed in 0.15 M sodium
cacodylate buffer, and then stained with 1% osmium tetroxide.
Next, a graded ethanol series (50%, 70%, 90%, 100%, and 100%)
was used to dehydrate the sample. A critical point drier (Leica
CPD 300, Vienna Austria) was used to dry the sample, which was
then sputter-coated with 6 nm iridium (Leica ACE 600, Vienna,
Austria). A Zeiss Merlin FE-SEM equipped with a Gemini II
electron column (Oberkochen, Germany) was used to image the
catheter with secondary electrons detected by the EverhartThornley secondary electron detector at an accelerating voltage
of 3 keV and a beam current of 200nm.

Urease Carriage Among S. aureus Strains
Bioinformatics analyses were used to determine the percentage of
sequenced S. aureus isolates in NCBI that carry ureC, which was
used as a marker for the carriage of the urease operon. A total of
10,290 S. aureus assemblies downloaded from NCBI were used.
Brieﬂy, open reading frames were identiﬁed for each assembly
using Prokka v1.14.5 and all open reading frames were clustered
using Roary v3.13.0 (Seemann, 2014; Page et al., 2015). The open
reading frame encoding ureC was then identiﬁed by sequence
match to the ureC gene in S. aureus strain JE2, and the presenceabsence matrix from Roary was used to calculate prevalence.

Urease Carriage Among HUC Isolates
To conﬁrm that the S. aureus HUC strains encode urease,
genomic DNA was extracted using the Promega Miniprep Kit
(Promega; cat # A1330) according to the manufacturer’s
guidelines, with the exception that 2 ug/ml of Lysostaphin
(Sigma; cat#) was added to the cells resuspended in P1 buffer
and incubated for 1 hr at 37°C to digest the staphylococcal cell
wall. PCR was then used to conﬁrm the presence of the ureC
gene, which encodes the active site within the urease enzyme, in
the genome. The ureC-Forward and ureC-Reverse primers
shown in Table 2 were created based on the JE2 genome

TABLE 2 | Primers used in this study.
Primer Name
ureC-Forward
ureC-Reverse
ureC-Forward-Mutant check
ureC-Reverse-Mutant check
Buster primer
ureC KO upstream for
ureC KO upstream rev
ureC KO downstream linker
ureC KO downstream rev

Sequence (5’-3’)

Citations

ATGAGCTTTAAAATGAACG
ATGTTCCTCCTAGAATAAG
GACGCAAAATCAATATACGAGCTT
CTTCATATGTTTGTGGATCAACG
GCTTTTTCTAAATGTTTTTTAAGTAAATCAAGTAC
ccgaattcGATTACAGATATCGAAATCGAGGCTA
TCATGATCTTTTTCCTCCTTTTTTATTCAC
GAATAAAAAAGGAGGAAAAAGATCATGAGAGGAACATAGAATGATTGTTGAAG
ccgtcgacCCTGTTGGAAACTGTGAATCACAG

This Study
This Study
This Study
This Study
Bae et al., 2008
This Study
This Study
This Study
This Study

Upper case sequences denote the genomic regions ampliﬁed based on the JE2 sequence obtained from NCBI and lower case sequences denote the restriction enzyme sites EcoRI
and SalI.
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SOEing PCR to generate a single amplicon. The single amplicon
was then PCR puriﬁed and cloned into the TOPO-PCR 2.1
(Thermo Fisher; cat # K45002) according to the manufacturer’s
protocol. The TOPO-PCR 2.1 ureC KO construct was then
transformed into DH5a chemically competent cells according
to the manufacturer’s protocol. The ureC KO construct that was
generated was then digested with EcoRI and SalI and ligated into
the plasmid pJB38, which was digested with the same restriction
enzymes, as previously described (Walker et al., 2013). The
ligation (pJB38 DureC) was transformed into chemically
competent DH5a, selecting on LB ampicillin, and colonies
were conﬁrmed for the correct construct using PCR and sanger
sequencing. Plasmid pJB38 DureC was extracted and
transformed into electrocompetent S. aureus cells (RN4220),
selecting on BHI chloramphenicol at 30°C. Electrocompetent
cells were created by subculturing RN4420 to an OD600 of 0.05 in
B2 media, which consists of 1% casein hydrolysate (Oxoid; cat #
LP0041), 2.5% yeast extract (Fisher; BP1422-500), 0.5% glucose
(Sigma; cat #G8270-1KG), 2.5% NaCl (Fisher; cat# S5671-500),
and 0.1% K2HPO4 (Sigma; cat # P9791-100G). The subculture
was then incubated for 2.5 hours, shaking at 37°C to an OD600 of
0.3-0.4. The cells were then harvested via centrifugation
(ThermoSientiﬁc SORVALL LEGEND X1R) at 5,000 rpm for
10 mins at 4°C and washed with decreasing amounts (1 volume,
½ volume, and ¼ volume) of ice cold, sterile water. The ﬁnal
wash was performed with 1/10 volume ice cold 10% glycerol and
the cells were resuspended in 1/250 volume 10% glycerol.
Electrocompetent cells were then stored at -80°C until ready
for use. Once electrocompetent UTI MRSA cells were created,
they were transformed with plasmid pJB38 DureC extracted from
RN4220. Transformants were selected at 42°C overnight on BHI
chloramphenicol. Colonies were screened for double
recombination and loss of the plasmid via PCR using the ureC
KO upstream forward and ureC KO downstream reverse primers
listed in Table 2 and for sensitivity to chloramphenicol,
respectively. Sanger sequencing was used to conﬁrm
the mutation.

downloaded from the NCBI database. The urease operon of K.
pneumonia C699 was conﬁrmed via genomic analysis, previously
performed in (Shropshire et al., 2021).

Generation of the Urease Transposon
Mutant Strains
The transposon mutant in ureC (ureC::tn) was obtained from the
Nebraska Transposon Mutant Library (BEI Resources). UTI
MRSA ureC::tn and JE2 ureC::tn mutants were generated via
transduction of the wildtype strains with lysates made from the
Nebraska Transposon Mutant Library ureC::tn mutant strain
using phage 11, as previously described (Walker et al., 2017).
Brieﬂy, a ureC::tn mutant lysate was generated by combining the
Nebraska Transposon Mutant Library strain containing the ureC
transposon mutation with phage 11 in melted top agar and
transferring the solution to a TSA plate containing 5 mM
calcium chloride. The top agar was allowed to cool and the
plates were incubated at 37°C overnight. Plates containing 30300 plaque forming units were selected, top agar was removed,
and plaques were extracted via centrifugation followed by
puriﬁcation with a 0.22 um syringe ﬁlter (Sigma; cat #
SLVGM33RS). The resulting phage lysate was then used to
introduce the ureC transposon mutation into the UTI MRSA
and JE2 background. For this, the UTI MRSA and JE2 strains
were streaked on a TSA slant and incubated overnight to create a
lawn. The bacteria were then resuspended in 1 mL TSA
supplemented with 5 mM calcium chloride. The puriﬁed ureC::
tn mutant phage lysate and the resuspended bacteria were then
incubated, shaking for 20 minutes at 37°C. Cold, sterile 20 mM
sodium citrate (Sigma; cat # W302600-1KG-K) was then added
to these cultures, which were then spun down, resuspended in 20
mM sodium citrate (Sigma; cat # W302600-1KG-K), and 100 ul
was spread on TSA plates containing 20 mM sodium citrate and
erythromycin. Colonies that grew were restreaked on TSA with
sodium citrate and erythromycin to select against any
contaminating phage 11 and to select for the ureC::tn
mutation, respectively. DNA was extracted as described above
and PCR was performed using the ureC-Forward-Mutant check
and Buster primers listed in Table 2 to conﬁrm the presence of
the ureC::tn mutation (UTI MRSA ureC::tn and JE2 ureC::tn).

Adapted Urease Activity Assay
For the adapted urease broth activity assay, strains from
overnight cultures were either i) subcultured (1:100 or 1:1000)
into urease broth with and without urea or ii) harvested by
centrifugation for 5 minutes at 10,000 g, washed with 1 volume of
1X Phosphate Buffered Saline (PBS), and resuspended in urease
broth with or without urea. Each strain was transferred to a 96well plate and tested in triplicate with at least two biological
replicates. Puriﬁed Jack Bean urease (Sigma; cat # 94281-1G),
strains grown in urease broth without urea, urease broth alone
with and without urea, and strains with mutants in urease were
included as controls. The OD was measured at 415 nm, 560 nm,
and 600 nm every 20 mins for 24 hrs, shaking at 37°C using a
BioTek Synergy|H1 microtiter plate reader (BioTek, Vermont).
The ratio of the OD detected at 560 nm compared to 415 nm is
used to calculate the color change that occurs following the
increase in the pH of the media, which is due to the urea
hydrolysis by urease. Furthermore, the use of urease broth
without urea takes into account any color change that is not

Generation of the ureC Clean
Deletion Strain
The clean ureC deletion in the UTI MRSA background (UTI
MRSA DureC) was generated via splicing overlap extension
(SOEing) PCR and homologous recombination, as previously
described (Walker et al., 2013). Brieﬂy, ~ 500 base pairs upstream
and downstream of the ureC gene were ampliﬁed from the
chromosomal DNA of UTI MRSA using the ureC KO primers
listed in Table 2. Care was taken to ensure the deletion was
inframe and did not disrupt the downstream genes of the rest of
the urease operon. The upstream and downstream amplicons
were then PCR puriﬁed using the Qiagen PCR puriﬁcation kit
(Qiagen; cat # 28106) and the ureC KO upstream for and ureC
KO downstream rev primers containing the EcoRI and SalI
restriction sites, respectively, listed in Table 2, were used in a
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due strictly to pH changes following urea hydrolysis, such as the
release of other byproducts during growth, that occurs during the
course of the experiment. Thus, the urease activity was calculated
by dividing the OD values at 560 nm by the OD values at 415 nm
and the urease activity was then normalized by dividing the OD
of each strain grown in urease broth containing urea by the same
strain grown in urease broth without urea.
Urease Activity =

OD560
OD415

Normalized Urease Activity
=

Average Urease Activity(wells with urea)
Average Urease Activity(wells without urea)
FIGURE 2 | S. aureus ureC carriage. PCR using the ureC-Forward and
ureC-Reverse primers (Table 2) was performed to conﬁrm the presence of
the ureC gene within clinical S. aureus isolates. The presence of an amplicon
around 1.6 Kb indicates all the strains tested encoded ureC. Numbers denote
lanes: (1) Ladder, (2) JE2, (3) UTI MRSA, (4) HUC 86, (5) HUC 86-02, (6) HUC
95, (7) HUC 97-02, (8) HUC 100, (9) HUC 100-01, (10) HUC 111-01C.

Statistical Analyses
Graphpad Prism 8.4.3 software was used to create all the
normalized urease activity graphs. All experiments were
performed with at least three replicates and repeated at least
twice. Graphs display the mean of the combined replicates and
error bars represent the standard deviation from the mean. An
additional statistical analysis, using the Mann Whitney U Test,
was performed on low urease producers to conﬁrm urease
activity detected among strains grown in the presence of urea
was signiﬁcantly different from that strain grown in the absence
of urea.

the course of the experiment. K. pneumonia urease could be
detected as early as 6 hours, with complete color change of the
agar plate around 24 hours. M. morganii also displayed signs of
urease activity as early as 6 hours, but complete color change of
the agar plate was delayed compared to K. pneumonia, occurring
around 34 hours. For the S. aureus strains, urease production
could be detected as early as 24 hours for UTI MRSA, HUC 95,
HUC 97-02, HUC 100, and HUC 100-01, 34 hours for JE2 and
HUC 86, and 50 hrs for HUC 86-02. Thus, all (9/9) S. aureus
strains tested were conﬁrmed to be urease-producers by the
Christensen Urea Agar method. All S. aureus ureC mutants
remained negative, as they did not display any color change
during the course of the experiment.

RESULTS
Urease Carriage
Previous reports indicate that urease detection among S. aureus
clinical isolates is low (25%-50%) (Bichler et al., 2002; Gad et al.,
2009; Flannigan et al., 2014). Yet a previous report suggested the
urease operon was present in a majority (>90%) of sequenced
isolates (Konieczna et al., 2012). Our analysis of 10,290
sequenced S. aureus isolates in NCBI found that ureC was
present in 93.1% of these strains, supporting the previous
report (Konieczna et al., 2012). Furthermore, to determine
whether a similar proportion of our S. aureus human urinary
catheter (HUC) isolates encoded urease, we used PCR to conﬁrm
the presence of the ureC gene, which is a marker for the operon.
Amplicons corresponding to an ~1.6 Kb band indicate that the
ureC gene was encoded by all HUC isolates (7/7), as well as the
urine-associated strain UTI MRSA, and the skin infection isolate
JE2 (Figure 2). Thus, all (9/9) S. aureus strains tested
encoded ureC.

Urease Broth Assay Validation
The adapted urease activity assay was evaluated using the
positive controls: Jack Bean urease enzyme (Figure 4A) and a
Proteus spp. strain (Figure 4B). The Jack Bean urease was used to
create standard curves to assess activity with decreasing
concentrations of the enzyme. The concentrations of pure Jack
Bean included 5U, 1U, 0.1U, 0.01U, and 0.001U. Urease activity
was detected immediately (within seconds) for the highest
concentrations of Jack Bean (5U and 1U) in urea containing
media. For the lower concentrations, a dose response was
observed, with activity detected around 20 minutes for 0.1U,
40 minutes for 0.01U, and 4 hours for 0.001U (Figure 4A). Next,
the urease activity of the Proteus spp. strain was assessed at
various bacterial concentrations. For the highest concentrations
of bacteria – overnight cultures resuspended in urease broth and
cultures diluted 1:100 in urease broth – activity was detected
around 20 and 40 minutes after the start of the assay, respectively
(Figure 4B). For the lowest concentrations of bacteria – cultures
diluted 1:1000 in urease broth – activity was detected around 1.5
hours after the start of the assay (Figure 4B). E. coli was used as a

Christensen Urea Agar Assay
To determine whether urease could be detected in a diverse set of
strains the current clinical test, the Christensen Urea Agar assay,
was used (Figure 3). A Proteus spp. strain was used as a positive
control and urease activity was rapidly detected, with the entire
plate turning pink by 6 hours. E. coli was used as a negative, nonurease producing control and displayed no color change during
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FIGURE 3 | Representative assay of the Christensen Urea Agar urease activity test. Christensen Urea Agar plates were streaked with a single colony of each bacterial
strain: Proteus spp., Escherichia coli, Klebsiella pneumonia, Morganella morganii, and Staphylococcus aureus strains including JE2, JE2 ureC::tn, UTI MRSA, UTI MRSA
DureC, UTI MRSA ureC::tn, HUC 86, HUC 86-02, HUC 95, HUC 97-02, HUC 100, HUC 100-01, and HUC 111-01C. Urease activity was detected by 6 hours in Proteus
spp., while no urease activity was detected in Escherichia coli. Urease activity was detected by 6 hours for both Klebsiella pneumonia and Morganella morganii. For
Staphylococcus aureus strains, urease activity in was detected by 24 hours in UTI MRSA, HUC 95, HUC 97-02, HUC 100, and HUC 100-01, 34 hours in JE2, HUC 86,
and HUC 111-01C, 50 hours in HUC 86-02. No urease activity was detected in JE2 ureC::tn, UTI MRSA DureC, or UTI MRSA ureC::tn.

concentration (Figure 4). For M. morganii, urease activity was
rapidly detected for the highest bacterial concentrations
(overnight resuspensions), ~20 minutes after the start of the
assay (Figure 4D). For lower bacterial concentrations of M.
morganii, diluted 1:100 and 1:1000 in urease broth, enzymatic
activity was detected about 40 minutes and 3 hours, respectively,
after the start of the assay (Figure 4D). For K. pneumonia, urease
activity could be detected as early as 40 minutes for the highest
bacterial concentration (overnight resuspension) and at 4 hours
for both the 1:100 and the 1:1000 dilutions (Figure 4E). For UTI

negative control. No urease activity was detected at any
concentration over the course of the 18-hour assay (Figure 4C).

Optimized Detection for Urease Producing
Uropathogens
M. morganii, K. pneumonia, and S. aureus (UTI MRSA and JE2)
strains, which are known urease producers, were selected to
optimize the urease detection assay for diverse species. Urease
activity was detected among various bacterial concentrations for
each species and urease activity correlated with bacterial
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FIGURE 4 | High throughput, semi-quantitative urease activity detection assay. The urease activity detection assay was validated with (A) Jack Bean enzyme,
(B) Proteus spp., and (C) Escherichia coli. A dose response curve (5U, 1U, 0.1U, and 0.001U) of Jack Bean urease was assessed. Enzymatic activity was detected
immediately for 5U and 1U, at 20 minutes for 0.1U, at 40 minutes for 0.01U, and at 4 hours for 0.001U. For the bacterial strains, increasing concentrations of
bacteria were assessed including 1:1000 and 1:100 dilutions of overnight cultures, as well as overnight cultures resuspended in urease broth, with urease activity
detected at 1.5 hours, 40 minutes, and 20 minutes for the Proteus spp. strain, respectively. The E coli strain did not display urease activity. Additional, diverse
urease-producing uropathogens at 1:1000 and 1:100 dilutions of overnight cultures, as well as overnight cultures resuspended in urease broth were assessed for
urease activity, including (D) Morganella morganii detected at 3 hours, 40 minutes, and 20 minutes, respectively; and (E) Klebsiella pneumonia detected at 4, 4, and
0.5 hours, respectively. For S. aureus strains urease activity was assessed at 1:100 dilutions of overnight cultures, as well as overnight cultures resuspended in
urease broth, with (F) UTI MRSA detected at 4 hours only at the highest bacterial concentration (overnight suspension). The (G) UTI MRSA ureC::tn and (H) UTI
MRSA DureC, were used as negative controls. No urease was detected over the course of the 18-hour experiment. Furthermore, (I) JE2 urease was detected at 4
hours only in the highest bacterial concentration tested (overnight suspension), while no urease was detected for (J) JE2 ureC::tn across the course of the 18-hour
experiment. Lastly, additional S. aureus strains were assessed for urease activity to determine the assay’s accuracy in detecting variable urease producers. Urease
activity was detected for (K) HUC 86 at 10 hours and 3 hours for the 1:100 dilution and overnight culture suspension, respectively; (L) HUC 86-02 at 6 hours and 2
hours for the 1:100 and overnight suspension, respectively; (M) HUC 95 at 20 hours only in overnight suspensions; (N) HUC 97-02 at 12 hours only in overnight
suspensions; (O) HUC 100 at 10 hours and 3 hours for the 1:100 dilution and overnight suspension, respectively; (P) HUC 100-01 at 4 hours and 1.5 hours for the
1:100 dilution and overnight suspension, respectively; and (Q) HUC 111-01C at 12 hours and 0.5 hour for the 1:100 dilution and overnight suspension, respectively.
Points represent the mean of three technical replicates and two biological replicates and error bars represent standard deviation from the mean.

Frontiers in Cellular and Infection Microbiology | www.frontiersin.org

9

March 2022 | Volume 12 | Article 859093

Duran Ramirez et al.

Semi-Quantitative Urease Detection Assay

after the start of the assay, at the highest bacterial concentration
(overnight suspension), with the lower bacterial concentration
(1:100 dilution) exhibiting enzymatic activity around 12 hours
(Figure 4Q). No urease activity was detected at the 1:1000
concentration (Figure S1). Lastly, to provide additional analyses
that further differentiate those isolates that display low activity
from those that display no activity in the presence of urea,
including E. coli, HUC 95, and HUC97-02, statistical analyses
comparing the enzymatic activity in the presence and absence of
urea were performed (Figure S2). The UTI MRSA strain was used
as a positive control and displayed signiﬁcantly more urease
activity at the ﬁnal time point assessed when grown in the
presence of urea compared to the absence, while no difference
was detected in the UTI MRSA DureC strain between the two
conditions (Figures S2A, B). Additionally, signiﬁcantly more
urease activity was detected for both HUC 95 and HUC 97-02
when the strains were grown with urea compared to without
(Figures S2C, D). Lastly, E. coli displayed no difference in detected
urease activity when the bacteria were grown in the presence of
urea compared to in its absence at the ﬁnal time point assessed,
while the Proteus spp. strain grown with urea had signiﬁcantly
more urease activity detected compared to the condition without
urea (Figures S2E, F).

MRSA, urease activity could be detected as early as 4 hours for
the overnight concentration, while no color change was detected
for the lower bacterial concentrations diluted 1:100 and 1:1000
(Figures 4F, S1). Furthermore, the UTI MRSA ureC::tn and UTI
MRSA DureC strains were used as non-urease producing
negative controls and no urease was detected over the 18-hour
time course (Figures 4G, H, S1). The well-characterized S.
aureus skin infection isolate JE2 was also assessed in the
adapted urease assay. Similarly to UTI MRSA, urease activity
in JE2 was only detected at the highest bacterial concentration,
with detection starting at 3 hours (Figures 4I, S1). JE2 ureC::tn
was used as a non-urease producing negative control, and no
urease was detected over the course of the 18-hour experiment
(Figures 4J, S1).

Assessing Urease-Producing S. aureus
Clinical Isolates With Adapted Assay
A panel of clinical catheter-associated S. aureus isolates were
selected to further assess the accuracy of the assay on so-called
difﬁcult to detect urease producers. For HUC 86, the adapted
urease broth assay detected enzymatic activity around 10 hours at
the highest bacterial concentration (overnight suspension)
(Figure 4K). This contrasted with the Christensen Urea Agar
plate assay, which detected urease activity around 34 hours.
Furthermore, at the 1:100 bacterial concentration, the adapted
urease assay detected some enzymatic activity with HUC 86 as
early as 3 hours. No urease activity was detected with HUC 86 at
the lowest dilution (1:1000) (Figure S1). Additionally, the adapted
assay detected urease activity for the serial isolate from the same
patient, HUC 86-02, more rapidly, around 2 hours at the highest
bacterial concentration (overnight suspension) and at 6 hours for
the 1:100 dilution (Figure 4L). No urease activity was detected at
the lowest bacterial concentration (1:1000) (Figure S1). For the
HUC 95 strain, urease activity was detected at 20 hours at the
highest bacterial concentration (overnight suspension), and no
urease activity was detected for the lower bacterial suspensions
(1:100 or 1:1000) (Figures 4M, S1). For the HUC 97-02 strain,
urease activity could begin to be detected at 12 hours at the highest
bacterial concentration (overnight suspension), but no urease
activity could be detected at the lower bacterial concentrations
(1:100 or 1:1000) (Figures 4N, S1). For the HUC 100 strain, urease
activity was ﬁrst detected for the 1:100 dilution approximately 3
hours after the start of the assay (Figure 4O). Urease activity was
next detected at 10 hours for the highest bacterial concentration
(overnight suspension). No urease activity was detected at the
lowest concentration (1:1000 suspension) (Figure S1). The HUC
100-01 strain, which is the serial isolate from the same patient as
HUC 100, displayed the quickest urease activity at the highest
bacterial concentration (overnight suspension) and was detected
approximately 1 hour after the start of the assay. Notably, the
lower bacterial concentration, 1:100, was also detected fairly
rapidly, around 4 hours after the start of the assay (Figure 4P).
No urease activity was detected at the lowest bacterial
concentration, 1:1000 dilution (Figure S1). Furthermore, in
contrast to the Christensen Urea Agar plate test, urease activity
for HUC 111-01C was rapidly detected, as early as 40 minutes
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Growth Curves of Urease-Producing HUC
Isolates in the Adapted Assay
To assess whether urease-producing uropathogens could grow in
the adapted assay media, bacterial growth was measured at an
OD600 (Figure S3). Proteus spp, E. coli, M. morganii, and K.
pneumonia all displayed similar growth phenotypes, with
increasing growth observed within the ﬁrst few hours of the
assay for all bacterial concentrations, before plateauing (Figures
S3A–D). The UTI MRSA and the isogenic ureC::tn and DureC
strains displayed slight increased growth during the ﬁrst few hours
at the highest bacterial concentration (overnight suspensions);
however, no growth was observed over the time course of the
experiment for the 1:100 and 1:1000 bacterial concentrations
(Figures S3E–G). For the JE2 and the isogenic ureC::tn, no
growth was detected for any of the bacterial concentrations over
the course of the experiment (Figures S3H–K). The HUC 86 and
HUC 86-02 displayed slight increased growth when diluted 1:100;
however, no growth was observed for the overnight or 1:1000
bacterial concentrations (Figures S3J, K). The HUC 95 strain
displayed growth at the highest bacterial concentration in the last
few hours of the experiment; however, no growth was observed for
the 1:100 and 1:1000 bacterial concentrations (Figures S3L).
Additionally, no growth was detected for HUC 97-02 at any
bacterial concentration over the course of the experiment
(Figure S3M). Steadily increasing growth was detected in the
HUC 100 and HUC 100-01 over the course of the experiment for
the 1:100 bacterial concentration; however, no growth was
detected for overnight and 1:1000 bacterial concentrations
(Figure S3N, O). Lastly, HUC 111-01C displayed increased
growth within the ﬁrst few hours of the assay at the 1:1000
bacterial concentration, but no growth was detected for
overnight and 1:100 bacterial concentrations (Figure S3P).
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which detected activity at 34, 50, 24, 24, 24, 24, and 34
hours, respectively.
While studies investigating urease regulation among “weak”
urease producers remains limited, two recent studies have indicated
S. aureus urease may be regulated via several pathways, including
the carbon catabolite pathway, CcpA, the quorum sensing system,
Agr, and a global regulator, CodY (Seidl et al., 2009; Zhou et al.,
2019). Speciﬁcally, for the Agr system in S. aureus, activation is cell
density dependent, with expression of the system occurring at high
bacterial concentrations due increased quantities of the
autoinducing peptide (AIP) (Zhou et al., 2019). Once a threshold
of AIP is reached, Agr upregulates the expression of downstream
genes, including urease. Notably, through this adapted urease assay,
a density dependent relationship was detected with higher bacterial
load correlating with higher urease activity and quicker detection
among the S. aureus strains. This supports the previous study that
indicated the agr quorum sensing system may be involved in urease
regulation. Furthermore, it may explain why some variability was
detected even among the highest bacterial concentration tested,
speciﬁcally since urease was detected in HUC 95 only after growth
occurred at the latest time points.
In addition to shortening the time of detection for urease
activity, our adapted assay also detected noticeable differences in
urease activity among the sequential HUC isolates. Speciﬁcally, the
adapted assay detected urease activity for the each of the sequential
isolates more quickly compared to the initial isolates (HUC 86-02 vs
HUC 86 and HUC 100-01 vs HUC 100). This is in contrast to the
Christensen Urea Agar method, which indicated the HUC 100 and
HUC 100-01 isolates exhibited similar urease activity, while HUC
86 produced more urease activity compared to the sequential isolate
HUC 86-02. Together, our data suggests that chronic urinary
catheterization may select for isolates with increased urease
activity. However, this is a small sample size and should be
assessed in future studies in more detail.
Importantly, the adapted assay allows for the manipulation of
various conditions to assess different aspects of urease
production. Speciﬁcally, we were able to alter the concentration
of bacteria to assess urease activity and production at different
growth stages and among diverse species of bacteria. While there
are limitations to this modiﬁed assay, they are similar to those for
the other clinical assays, including the Christensen Urea Agar
method and the RUT test. Speciﬁcally, this assay is also limited
by the time the assay can accurately detect urease activity due to
the risk of false positives caused by bacterial growth byproducts
or other non-urease related pH changes in the media. However,
the inclusion of non-bacteria containing controls, non-urea
containing controls, and non-urease producing strains are
essential for mitigating these limitations. Additionally, the
current composition and conditions may need to be further
adjusted to test for other uropathogens or to accommodate for
other, as yet unknown environmental stimuli or factors that
affect urease regulation among these diverse species. Since the
assay is easily adaptable, these adjustments can be made using
validated controls. Thus, this adaptable, high throughput, semiquantitative assay can facilitate future studies that dissect
differences in urease regulation or activity in a broad range of

DISCUSSION
Over 1 million cases of CAUTIs occur each year (Ronald, 2003;
Trautner and Darouiche, 2004; Cope et al., 2009; Trautner, 2010;
Nicolle, 2012; Flores-Mireles et al., 2015; Chenoweth and Saint,
2016). Unlike uncomplicated UTIs in healthy individuals, CAUTIs
are caused by a broader range of pathogens that continue to be
understudied (Konieczna et al., 2012; Wagenlehner et al., 2012;
Weiner et al., 2016). In addition, chronically catheterized
individuals are at a high risk for ASB, which when caused by
urease-producing bacteria can result in catheter blockages,
pyelonephritis, and lead to a decrease in quality of life (Warren
et al., 1994; Hedelin, 2002; Broomﬁeld et al., 2009; Flores-Mireles
et al., 2015; Nicolle, 2019). With the projected increase in urinary
catheterizations due to an aging population, the importance of
understanding urease activity among agents other than P. mirabilis
is apparent, as urease production is a key component causing
catheter encrustations that greatly reduce the efﬁcacy of catheters,
decrease the quality of life of patients, and increase the risk of UTIs
(Broomﬁeld et al., 2009; Trautner, 2010). However, current assays
to detect urease activity favors high urease producers like P.
mirabilis. Speciﬁcally, our data from Christensen Urea Agar
plates demonstrate that rapid detection only works well for
Proteus spp. The diversity of urease-producing uropathogens
highlights the importance of developing an assay that can detect
urease activity for a broader range of microbes that may require
different culture conditions. Furthermore, the current clinical assays
are primarily designed for qualitative detection of urease activity,
leaving little room for more complex studies focused on regulation,
production, or activity.
We developed a versatile, high throughput assay to allow us to
detect urease activity among diverse urease-producing CAUTI
pathogens. We validated the assay utilizing Jack Bean urease
enzyme and Proteus spp. as positive controls and E. coli as a
negative control. Importantly, when compared to the Christensen
Urea Agar plate method, the adapted assay more rapidly detected
urease activity for a wide range of species, including Proteus spp., K.
pneumonia, M. morganii, and S. aureus. Furthermore, while all
clinical S. aureus strains tested were conﬁrmed to encode ureC,
urease activity in these isolates was highly variable. Speciﬁcally for
the adapted urease assay, no urease activity was detected at the
lowest concentration (1:1000 dilution), yet at the 1:100 dilution
around 55% (5/9) of S. aureus strains were identiﬁed as urease
producers. This percentage matches what is typically reported in the
clinical setting, indicating a 1:100 dilution may mimic the results
from the current Christensen Urea Agar method. However, our
PCR results indicate all S. aureus strains encode urease and our
adapted assay more closely replicated those results using the highest
bacterial concentration. Furthermore, our adapted assay more
quickly detected urease activity in UTI MRSA and JE2, at 4 hours
and 3 hours, compared to the Christensen Urea Agar method,
which detected activity at 24 hours and 34 hours, respectively.
Additionally, urease activity for the HUC isolates, HUC 86, HUC
86-02, HUC 95, HUC 97-02, HUC 100, HUC 100-01, and HUC
111-01C, was detected at 10, 2, 20, 12, 3, 1.5, and 0.5 hours with the
adapted assay compared to the Christensen Urea Agar method,
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urease-producing pathogens by modifying the culture
conditions. By studying the regulation of the urease enzyme,
better treatments and/or potential therapies can be developed to
potentially reduce CAUTIs, and improve the quality of life for
catheterized individuals.
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Rosenthal, C. B., et al. (2013). The Staphylococcus Aureus ArlRS TwoComponent System is a Novel Regulator of Agglutination and Pathogenesis.
PloS Pathog. 9 (12), e1003819 (1–17). doi: 10.1371/journal.ppat.1003819
Walker, J. N., Flores-Mireles, A. L., Lynch, A. J. L., Pinkner, C., Caparon, M. G.,
Hultgren, S. J., et al. (2020). High-Resolution Imaging Reveals Microbial
Bioﬁlms on Patient Urinary Catheters Despite Antibiotic Administration.
World J. Urol. 38 (9), 2237–2245. doi: 10.1007/s00345-019-03027-8
Walker, J. N., Flores-Mireles, A. L., Pinkner, C. L., Schreiber, H., Joens, M. S., Park,
A. M., et al. (2017). Catheterization Alters Bladder Ecology to Potentiate
Staphylococcus Aureus Infection of the Urinary Tract. Proc. Natl. Acad. Sci.
U. S. A. 114 (41), E8721–e8730. doi: 10.1073/pnas.1707572114
Warren, J. W., Muncie, H. L.Jr., Hebel, J. R., and Hall-Craggs, M. (1994). LongTerm Urethral Catheterization Increases Risk of Chronic Pyelonephritis and
Renal Inﬂammation. J. Am. Geriatr. Soc. 42 (12), 1286–1290. doi: 10.1111/
j.1532-5415.1994.tb06513.x
Weiner, L. M., Webb, A. K., Limbago, B., Dudeck, M. A., Patel, J., Kallen, A. J.,
et al. (2016). Antimicrobial-Resistant Pathogens Associated With HealthcareAssociated Infections: Summary of Data Reported to the National Healthcare
Safety Network at the Centers for Disease Control and Preventio-2014. Infect.
Control Hosp Epidemiol. 37 (11), 1288–1301. doi: 10.1017/ice.2016.174
Zhou, C., Bhinderwala, F., Lehman, M. K., Thomas, V. C., Chaudhari, S. S.,
Yamada, K. J., et al. (2019). Urease is an Essential Component of the Acid
Response Network of Staphylococcus Aureus and is Required for a Persistent
Murine Kidney Infection. PloS Pathog. 15 (1), e1007538 (1–23). doi: 10.1371/
journal.ppat.1007538

Gatermann, S., John, J., and Marre, R. (1989). Staphylococcus Saprophyticus
Urease: Characterization and Contribution to Uropathogenicity in
Unobstructed Urinary Tract Infection of Rats. Infect. Immun. 57 (1), 110–
116. doi: 10.1128/iai.57.1.110-116.1989
Gatermann, S., and Marre, R. (1989). Cloning and Expression of Staphylococcus
Saprophyticus Urease Gene Sequences in Staphylococcus Carnosus and
Contribution of the Enzyme to Virulence. Infect. Immun. 57 (10), 2998–
3002. doi: 10.1128/iai.57.10.2998-3002.1989
Hedelin, H. (2002). Uropathogens and Urinary Tract Concretion Formation and
Catheter Encrustations. Int. J. Antimicrob. Agents 19 (6), 484–487.
doi: 10.1016/s0924-8579(02)00095-x
Hu, L. T., Nicholson, E. B., Jones, B. D., Lynch, M. J., and Mobley, H. L. (1990).
Morganella Morganii Urease: Puriﬁcation, Characterization, and Isolation of
Gene Sequences. J. Bacteriol. 172 (6), 3073–3080. doi: 10.1128/jb.172.6.30733080.1990
Klein, R. D., and Hultgren, S. J. (2020). Urinary Tract Infections: Microbial
Pathogenesis, Host-Pathogen Interactions and New Treatment Strategies. Nat.
Rev. Microbiol. 18 (4), 211–226. doi: 10.1038/s41579-020-0324-0
Konieczna, I., Zarnowiec, P., Kwinkowski, M., Kolesinska, B., Fraczyk, J.,
Kaminski, Z., et al. (2012). Bacterial Urease and its Role in Long-Lasting
Human Diseases. Curr. Protein Pept. Sci. 13 (8), 789–806. doi: 10.2174/
138920312804871094
Kosikowska, P., and Berlicki, Ł. (2011). Urease Inhibitors as Potential Drugs for
Gastric and Urinary Tract Infections: A Patent Review. Expert Opin. Ther. Pat.
21 (6), 945–957. doi: 10.1517/13543776.2011.574615
Meddings, J., Rogers, M. A., Krein, S. L., Fakih, M. G., Olmsted, R. N., and Saint, S.
(2014). Reducing Unnecessary Urinary Catheter Use and Other Strategies to
Prevent Catheter-Associated Urinary Tract Infection: An Integrative Review.
BMJ Qual Saf. 23 (4), 277–289. doi: 10.1136/bmjqs-2012-001774
Nicholson, E. B., Concaugh, E. A., Foxall, P. A., Island, M. D., and Mobley, H. L.
(1993). Proteus Mirabilis Urease: Transcriptional Regulation by UreR.
J. Bacteriol 175 (2), 465–473. doi: 10.1128/jb.175.2.465-473.1993
Nicolle, L. E. (2012). Urinary Catheter-Associated Infections. Infect. Dis. Clin.
North Am. 26 (1), 13–27. doi: 10.1016/j.idc.2011.09.009
Nicolle, L. (2019). Symptomatic Urinary Tract Infection or Asymptomatic
Bacteriuria? Improving Care for the Elderly. Clin. Microbiol. Infect. 25 (7),
779–781. doi: 10.1016/j.cmi.2019.03.013
Page, A. J., Cummins, C. A., Hunt, M., Wong, V. K., Reuter, S., Holden, M. T. G.,
et al. (2015). Roary: Rapid Large-Scale Prokaryote Pan Genome Analysis.
Bioinformatics 31 (22), 3691–3693. doi: 10.1093/bioinformatics/btv421
Peasah, S. K., McKay, N. L., Harman, J. S., Al-Amin, M., and Cook, R. L. (2013).
Medicare Non-Payment of Hospital-Acquired Infections: Infection Rates
Three Years Post Implementation. Medicare Medicaid Res. Rev. 3 (3), E1–
E13. doi: 10.5600/mmrr.003.03.a08
Pelling, H., Nzakizwanayo, J., Milo, S., Denham, E. L., MacFarlane, W. M., Bock, L.
J., et al. (2019). Bacterial Bioﬁlm Formation on Indwelling Urethral Catheters.
Lett. Appl. Microbiol. 68 (4), 277–293. doi: 10.1111/lam.13144
Richmond, S., and Yep, A. (2019). Quantiﬁcation of Urease Activity. Methods Mol.
Biol. 2021, 85–96. doi: 10.1007/978-1-4939-9601-8_9
Ronald, A. (2003). The Etiology of Urinary Tract Infection: Traditional and
Emerging Pathogens. Dis. Mon. 49 (2), 71–82. doi: 10.1067/mda.2003.8
Seemann, T. (2014). Prokka: Rapid Prokaryotic Genome Annotation.
Bioinformatics 30 (14), 2068–2069. doi: 10.1093/bioinformatics/btu153
Seidl, K., Müller, S., François, P., Kriebitzsch, C., Schrenzel, J., Engelmann, S., et al.
(2009). Effect of a Glucose Impulse on the CcpA Regulon in Staphylococcus
Aureus. BMC Microbiol. 9, 95. doi: 10.1186/1471-2180-9-95
Shropshire, W. C., Dinh, A. Q., Earley, M., Komarow, L., Panesso, D., Rydell, K.,
et al. (2021). Accessory Genomes Drive Independent Spread of CarbapenemResistant Klebsiella Pneumoniae Clonal Groups 258 and 307. medRxiv 1–47.
doi: 10.1101/2021.08.04.21261380
Sigurdarson, J. J., Svane, S., and Karring, H. (2020). Development of a M9-Based
Urea Medium (M9U) for Sensitive and Real-Time Monitoring of Ureolytic

Frontiers in Cellular and Infection Microbiology | www.frontiersin.org

Conﬂict of Interest: The authors declare that the research was conducted in the
absence of any commercial or ﬁnancial relationships that could be construed as a
potential conﬂict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their afﬁliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2022 Duran Ramirez, Gomez, Obernuefemann, Gualberto and Walker.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) and the copyright owner(s) are credited and
that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.

13

March 2022 | Volume 12 | Article 859093

